Compare SXT & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXT | CRSP |
|---|---|---|
| Founded | 1882 | 2013 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.7B |
| IPO Year | 1994 | 2016 |
| Metric | SXT | CRSP |
|---|---|---|
| Price | $88.22 | $57.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 17 |
| Target Price | ★ $110.00 | $70.00 |
| AVG Volume (30 Days) | 375.6K | ★ 1.3M |
| Earning Date | 05-18-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | ★ 7.48 | N/A |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $1,396,499,000.00 | $289,590,000.00 |
| Revenue This Year | $9.05 | $1,070.60 |
| Revenue Next Year | $8.65 | $100.28 |
| P/E Ratio | $28.93 | ★ N/A |
| Revenue Growth | N/A | ★ 9169.85 |
| 52 Week Low | $67.79 | $30.06 |
| 52 Week High | $121.54 | $78.48 |
| Indicator | SXT | CRSP |
|---|---|---|
| Relative Strength Index (RSI) | 37.05 | 53.39 |
| Support Level | $82.60 | $51.64 |
| Resistance Level | $98.95 | $60.63 |
| Average True Range (ATR) | 3.06 | 3.11 |
| MACD | -0.62 | 0.19 |
| Stochastic Oscillator | 5.74 | 53.43 |
Sensient Technologies Corp manufactures and markets natural and synthetic colors, flavors, and other specialty ingredients. Sensient's offerings are predominantly applied to consumer-facing products, including food and beverage, cosmetics and pharmaceuticals, nutraceuticals, and personal care industries. Its principal products are flavors, flavor enhancers, ingredients, extracts, and bionutrients, essential oils, dehydrated vegetables and other food ingredients, natural and synthetic food and beverage colors, and others. The company's reportable segments are; Flavors & Extracts, which derive key revenue, Color, Asia Pacific, and Corporate and Other. Geographically, the company generates maximum revenue from North America, followed by Europe, Asia-Pacific, and other regions.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.